Inscopix: scoping out better preclinical models via live brain imaging
Inscopix uses brain imaging to make better preclinical models for CNS diseases
With a platform to perform in vivo brain imaging, Inscopix Inc. is aiming to fix the poor predictive power of preclinical animal models for CNS diseases. Its advantage is the ability to use changes in neural circuits, rather than behavioral readouts, as a measure of disease.
Founder and CEO Kunal Ghosh believes the notorious track record of rodent models of neurological diseases is rooted in the inadequacy of standard behavioral tests used to reflect symptoms or to read out disease biology.
“For better or worse, all preclinical models cause skepticism, but I think we can do better with a circuit-based